Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Berm,
Interestingly our medicated depressives have been absent for a few days! Looking forward for some good news, maybe a while away though as it takes time to prove this science/IP. I do think we have something special though, let LD do what she is good at.
ATB
Bunsie,
Sorry just noticed your 18.38 - thanks , will try!
Berm,
Yes, it has been a long journey with SCLP, please keep focused on the final outcome, it has been a changing road somewhat which has delayed possible returns.
Hang in there
ATB
LL -
All I know is that in the time I've been holding Scancell shares, they could have built one tunnel and be half way through a second :)
No worries, I'm sure you can remember way back when Eurotunnel seemed like it might be a bit of a folly. Just in case, here is one from the archives. https://www.latimes.com/archives/la-xpm-1991-06-02-mn-327-story.html
I really hope that we don't have to wait so long for Scancell's commercial viability to be proven.
Thanks for reply LL
Either, but I am hoping covid-19 vax news solution by other has less of a downward spike.
I forgot to include on the upwards spike any news relating to funding, deals, etc.
For me, Scancell is a bit like Eurotunnel, during the building phase as was when the highest price early in their history was when it actually looked like it would be successful.
LochinvarLass
Are you talking about COVID-19 vax or SCIB1?
Tony,
In terms of driving the share price up, I think the key milestones are related to the completion of clinical trials showing a positive impact.
In terms of driving the share price down, the discovery of a 20-100% effective solution ahead of ours.
Due to air arse Oles ... Gap filling by dentists will not be allowed .. those engaged in Gap filling are doing so illegally
further details contact the NHS Covid Task force
Here is another Gaps....
Gut and Psychology Syndrome: Natural Treatment for Autism, Dyspraxia, A.D.D., Dyslexia, A.D.H.D., Depression, Schizophrenia, 2nd Edition, haha
ATB
Gap filing - too complicated for me!!!
Can anyone explain in simple terms what we are waiting on to drive this share price? Any key milestones?
*hopeful rather than hopefully (fingers on automatic)
C7, I think I said when the results were in, rather than "proven". I am hopefully that the results will show significant improvements over others in the same / similar product field.
I don't know if proven includes the publication of a peer reviewed article on the results. I personally fear there will be so much "news" in this arena that even a significant discovery could be buried by those who have cultivated the health journos with other "stuff".
As mentioned, since the site is also testing the Oxford vaccine, they can see first hand the problems they will encounter with a 2nd gen Coivd vaccine (which is good not only for this, but the next ones).
I am hoping that the cancer trials will take on board the new clinical trial model used by Oxford to get results faster. I believe Flaskdata in Israel also champions ways to ensure that trial protocols stay at a high level plus real time reporting of patient datapoints.
Interesting part guys................
Gaps must be filled
There is an assumption amongst some traders that gaps must be filled, meaning that the price is expected to return to the gap area at a future date.
Breakaway and runaway gaps are believed to have a lower probability of being filled. This is due to the assumption that the market event which caused this type of gap to occur carries a strong directional momentum. Trading for a gap fill would therefore equate to trading against this momentum and trading against the newly formed trend.
Traders looking to trade a ‘gap fill’ might prefer to do so in the event of an exhaustion gap. An exhaustion gap suggests the directional move to be capitulating and possibly reversing course. This assumes a higher probability to trading for a ‘gap fill’
Inan,
A gap appears between my ears sometimes!!
ATB
in the SP ...
missed that bit
Bunsie, Crackin can only read numbers .. the technical descriptions presented by a Scancell RNS are challenging for many inc. Crackin , Scancell rarely mention the word Gap .. other than a "Gap" in the market to allow us the be commercial ..
example ... we don't add toxicity to check points .. thus a "Gap" exists as many combo's do ... ie chemo
Gap in context is a useful word ...
not sure many people Top Up or buy just because they see a Gap ..
WTP
I am invested here purely on the IP/Science, just thought the article explained it quite well
ATB
Typo "...probably the best article about gaps"
@crackin, as mentioned fair dues, i either missed that post originally, and/or it went over my head at the time, and/or it i ignored as there is a lot of "rub it in your noses" type/trader type/doom mongering type rhetoric. Although in fairness that particular post wasn't that bad. And yes hand's up guity of not being as neutral as I can be which is a another (main?) reason. Obviously no obligation to, but perhaps a more explanitory approach to your messages would help people like myself, otherwise as i say it comes across as doom mongering (to us less informed).
@bunsie, thanks very useful artical, every day is a school day! I'd been reading about them recently but that's proba
What type of gap was created on the Covid RNS day then? A breakaway?
Does this explain the 50k/100k sells then, i.e. to fill the gap. Once the gap has been filled the selling pressure should stop? I.e. back to a neutral state, so to speak?
LL, good post. I am not so sure proven is the word, as MOD1 and even more SCIB1 are proven enough to go for trial , nd the problem with receiving any updates here is until we know eactly where and when we can go to trial, what can they say more in an update??
With regard to Biontech/TCR we can only expect an update if the collaboration is extended or a commercial deal comes from it, which is exactly the same for Avidamab and the three collaborations we have which the first of is coming towards it"s 12 month period. However, IF we can get a Commercial Deal on the first it is my opinion that could expedite deals on the other two before the 12 month period perhaps.
Given this and the big question mark over when trials can resume, that leaves COVIDITY. I was pleased to hear we now feature in the who list, but as Bermudashorts says it means no more than that at this stage. So the importance of a funding deal for COVIDITY is palpable, it could set so many wheels in motion needless to say add value and interest in any funding that may come late for the SCIB1 trial.
Once again I do believe we will get a raise similar to the Vulpes one last year, remeber VULPES cannot exceed a 29.99% holding, and also when VULPES bought their first tranche the hare did rise to 9.4p briefly from the mid 3s at one stage. It is a hard one, an update is further price sensitive information that we are not aware of, I think from that it is clear what we need to happen to trigeer any RNS. Really hoping we get this funding for COVIDITY, it could well be the turning point for us, and also help to validate SCIB1 further.
If I remember rightly, at the last AGM we we were told we would be informed when the first Patient is dosed, (SCIB! Combo).
I thought they would only issue another RNS on receipt of the results, not of the start of a trial which has already been announced.
That said, I'm not sure why they don't have someone, as GSK and many others do who looks after their social media and news.
https://www.ig.com/uk/trading-strategies/how-to-trade-using-price-gap-analysis-190802